Drug for targeted treatment of diabetic peripheral neuropathy and neuroprotective drug for regulating proliferation function of schwann cells
By targeting diabetic peripheral neuropathy with the functional peptide CAP229 and regulating the proliferation function of Schwann cells, the problem of insignificant effects of existing treatments has been solved, achieving neuroprotection and functional recovery.
CN120392966BActive Publication Date: 2025-10-21XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202510903045.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-01
- Publication Date
- 2025-10-21
- Estimated Expiration
- 2045-07-01
AI Technical Summary
Technical Problem
Currently, there is a lack of effective and fundamental treatments for diabetic peripheral neuropathy. Existing treatments mainly provide symptomatic relief, which is not very effective and seriously affects patients' quality of life.
Method used
The functional peptide CAP229 is used to target diabetic peripheral neuropathy, regulate the proliferation function of Schwann cells, and promote neuroprotection.
Benefits of technology
It significantly improves the symptoms of diabetic peripheral neuropathy, increases the mechanical pain threshold, restores nerve conduction function, maintains the integrity of myelin sheath structure, and alleviates nerve demyelinating lesions.
✦ Generated by Eureka AI based on patent content.
Abstract
The application discloses a drug for targeted treatment of diabetic peripheral neuropathy and a nerve protection drug for regulating Schwann cell proliferation function, relates to the technical field of biological medicine, and the drug for targeted treatment of diabetic peripheral neuropathy comprises a functional polypeptide CAP229, and the amino acid sequence of the functional polypeptide CAP229 is shown as SEQ ID NO:1. The functional polypeptide CAP229 is applied to a protein drug for targeted treatment of diabetic peripheral nerve demyelination, a new selection of targeted treatment of diabetic peripheral neuropathy is provided, the CAP229 polypeptide has the advantages of small molecule, stable structure, endogenous source and the like, is suitable for a protein drug platform and a gene delivery strategy, has good conversion prospect, can relieve myelin loss in diabetic neuropathy in vitro and in an animal model, and can be used for constructing a functional screening platform and a high-throughput evaluation model.
Need to check novelty before this filing date? Find Prior Art